Cantor Fitzgerald Issues Positive Outlook for YMAB Earnings

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) - Investment analysts at Cantor Fitzgerald boosted their FY2024 EPS estimates for Y-mAbs Therapeutics in a research note issued to investors on Monday, November 11th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company will earn ($0.66) per share for the year, up from their prior estimate of ($0.67). Cantor Fitzgerald currently has a "Overweight" rating and a $20.00 price objective on the stock. The consensus estimate for Y-mAbs Therapeutics' current full-year earnings is ($0.65) per share.

Several other research analysts also recently weighed in on YMAB. HC Wainwright reaffirmed a "buy" rating and set a $22.00 target price on shares of Y-mAbs Therapeutics in a research note on Tuesday, August 13th. Canaccord Genuity Group raised Y-mAbs Therapeutics to a "strong-buy" rating in a research note on Tuesday, August 13th. Morgan Stanley reduced their target price on Y-mAbs Therapeutics from $12.00 to $11.00 and set an "underweight" rating for the company in a research note on Tuesday, August 13th. BMO Capital Markets reduced their price objective on Y-mAbs Therapeutics from $26.00 to $25.00 and set an "outperform" rating for the company in a research note on Tuesday, August 13th. Finally, Canaccord Genuity Group reissued a "buy" rating and issued a $26.00 price objective on shares of Y-mAbs Therapeutics in a research note on Tuesday, August 13th. One investment analyst has rated the stock with a sell rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Y-mAbs Therapeutics has an average rating of "Moderate Buy" and an average price target of $21.14.

Y-mAbs Therapeutics Stock Down 9.0 %

Shares of YMAB stock traded down $1.19 during trading hours on Thursday, hitting $11.99. 203,886 shares of the company's stock were exchanged, compared to its average volume of 329,062. The firm has a market cap of $537.02 million, a P/E ratio of -22.50 and a beta of 0.68. The firm has a 50 day moving average of $14.08 and a two-hundred day moving average of $13.13. Y-mAbs Therapeutics has a fifty-two week low of $5.04 and a fifty-two week high of $20.90.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last released its quarterly earnings results on Friday, November 8th. The company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.02). The business had revenue of $18.46 million during the quarter, compared to analyst estimates of $23.38 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same period in the previous year, the company posted ($0.18) EPS.

Insiders Place Their Bets

In other Y-mAbs Therapeutics news, COO Joris Wilms sold 5,000 shares of the firm's stock in a transaction on Monday, August 26th. The stock was sold at an average price of $14.69, for a total value of $73,450.00. Following the completion of the sale, the chief operating officer now directly owns 30,600 shares of the company's stock, valued at $449,514. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Y-mAbs Therapeutics news, COO Joris Wilms sold 5,000 shares of the firm's stock in a transaction on Monday, August 26th. The stock was sold at an average price of $14.69, for a total value of $73,450.00. Following the completion of the sale, the chief operating officer now directly owns 30,600 shares of the company's stock, valued at $449,514. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Thomas Gad sold 30,000 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $12.97, for a total value of $389,100.00. Following the transaction, the insider now owns 67,681 shares of the company's stock, valued at approximately $877,822.57. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 100,000 shares of company stock valued at $1,338,100 in the last three months. 22.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Y-mAbs Therapeutics

A number of hedge funds have recently modified their holdings of the business. Dimensional Fund Advisors LP grew its holdings in shares of Y-mAbs Therapeutics by 15.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company's stock worth $5,853,000 after purchasing an additional 65,732 shares during the period. Millennium Management LLC boosted its holdings in Y-mAbs Therapeutics by 23.8% during the 2nd quarter. Millennium Management LLC now owns 349,784 shares of the company's stock valued at $4,225,000 after acquiring an additional 67,233 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in Y-mAbs Therapeutics by 9.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 279,577 shares of the company's stock valued at $3,676,000 after acquiring an additional 23,982 shares during the period. Squarepoint Ops LLC boosted its holdings in Y-mAbs Therapeutics by 143.4% during the 2nd quarter. Squarepoint Ops LLC now owns 126,389 shares of the company's stock valued at $1,527,000 after acquiring an additional 74,452 shares during the period. Finally, Bank of New York Mellon Corp boosted its holdings in Y-mAbs Therapeutics by 8.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 120,954 shares of the company's stock valued at $1,461,000 after acquiring an additional 8,974 shares during the period. 70.85% of the stock is currently owned by hedge funds and other institutional investors.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.